Refine
Year of publication
Document Type
- Preprint (786)
- Article (647)
- Conference Proceeding (4)
- Doctoral Thesis (1)
- Working Paper (1)
Language
- English (1432)
- German (6)
- Multiple languages (1)
Has Fulltext
- yes (1439)
Is part of the Bibliography
- no (1439)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- BESIII (10)
- e +-e − Experiments (10)
- LHC (9)
- Branching fraction (7)
- Particle and Resonance Production (7)
- Heavy-ion collision (6)
- HIV (5)
- ALICE experiment (4)
- Charm Physics (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Inverse kinematics (4)
- Jets (4)
- Lepton colliders (4)
- Quark-Gluon Plasma (4)
- Quasi-free scattering (4)
- Spectroscopy (4)
- ALICE (3)
- Biomarkers (3)
- COVID-19 (3)
- Charmed mesons (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Hadronic decays (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Oncology (3)
- Osteoporosis (3)
- Particle and resonance production (3)
- QCD (3)
- Quarkonium (3)
- Spectroscopic factors (3)
- breast cancer (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Antiretroviral therapy (2)
- Beauty production (2)
- Bone density (2)
- Branching fractions (2)
- CT (2)
- Cirrhosis (2)
- Diagnostic markers (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Epilepsy (2)
- Exotics (2)
- Früherkennung (2)
- Heart failure (2)
- Heavy Quark Production (2)
- Hypertension (2)
- Inflammation (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Liver diseases (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Nuclear reactions (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Seizure (2)
- Shell model (2)
- Single electrons (2)
- Single-particle states (2)
- Spine (2)
- biomarker (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- pelvic packing (2)
- reference values (2)
- screening (2)
- 900 GeV (1)
- ABC transporters (1)
- ALICE detector (1)
- ALK (1)
- APRI (1)
- ATPases (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Acute coronary syndrome (1)
- Alpha-synuclein (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antiviral therapy (1)
- Aortic valve (1)
- Apoptosis (1)
- Artesunate (1)
- Atherosclerosis (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atrial fibrillation (1)
- B cell receptor (1)
- B cell subpopulations (1)
- BESIII detector (1)
- BRCA1 (1)
- BRCA2 (1)
- Bacterial genomics (1)
- Bayesian inference (1)
- Beam loss (1)
- Bhabha (1)
- Biomarker (1)
- Bipolar disorder (1)
- Bleeding (1)
- Blood plasma (1)
- Blood pressure (1)
- Body mass index (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- Breast cancer (1)
- C-clamp (1)
- C3M (1)
- C4M (1)
- CD16 (1)
- CD56 (1)
- COVID 19 (1)
- CP violation (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer treatment (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell-to-Cell Spread (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Chemoradiotherapy (1)
- Child (1)
- Children (1)
- Chronic obstructive pulmonary disease (1)
- Circular accelerators (1)
- Clinical study (1)
- Clinical variation (1)
- Cohort studies (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex II (1)
- Computed tomography, X-ray (1)
- Consensus (1)
- Consensus document (1)
- Contrast agent (1)
- Costs (1)
- Cross section (1)
- Cross sections (1)
- Culture positive (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- De-isolation (1)
- Death rates (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Digestive system procedures (1)
- Direct nuclear reactions (1)
- Direct reactions (1)
- Docetaxel (1)
- Drug screens (1)
- Dual-energy computed tomography (1)
- Economics (1)
- Eicosanoids (1)
- Ejection fraction (1)
- Elderly (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Elliptic flow (1)
- Endocrinology (1)
- Endoscopy (1)
- Ephrin-B2–EphB4 (1)
- Esophagectomy (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Exercise training (1)
- Exosomes (1)
- FAPI PET (1)
- FIB-4 (1)
- FOS: Physical sciences (1)
- Falciparum (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First-line combination antiretroviral therapy (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Forschung (1)
- Frailty (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics (1)
- German PID-NET registry (1)
- Gleason Grade Group (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2-positive (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health economics (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion storage ring (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Hepatitis B virus (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Herniated disk (1)
- High Energy Physics - Experiment (hep-ex) (1)
- High-energy neutron detection (1)
- Human behaviour (1)
- Hyperons (1)
- ICL (1)
- ICL V4c (1)
- INR (1)
- IgG substitution therapy (1)
- Image processing (1)
- Implantable cardioverter-defibrillator (1)
- In-TIPS thrombosis (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Initial state radiation (1)
- Intensity interferometry (1)
- International normalized ratio (1)
- Intervertebral disc displacement (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- K0S (1)
- Kidney diseases (1)
- Lehre (1)
- Leukemias (1)
- Liver (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- MHC (1)
- MRI (1)
- MTOR inhibitor (1)
- MYCN amplification (1)
- Malaria (1)
- Masquelet technique (1)
- Material budget (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molecular diagnostic testing (1)
- Molecular neuroscience (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- Myopia (1)
- NK cells (1)
- NMR spectroscopy (1)
- Nanoscale biophysics (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neutrinos (1)
- Non-small cell lung cancer (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- One-nucleon removal (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- Optical tweezers (1)
- Orbital electron capture (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PDE‐5‐inhibitor (1)
- PID prevalence (1)
- PYTHIA (1)
- Pacemaker (1)
- Parkinson’s disease (1)
- Particle phenomena (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Percutaneous (1)
- Personalized medicine (1)
- Phakic (1)
- Phantoms (imaging) (1)
- Phospholipids (1)
- Photon counting (1)
- Physical activity (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Point-of-care testing (1)
- Polarization (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Prevention (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Protease inhibitor therapy (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- QGP (1)
- Quantitative Imaging (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quinine (1)
- RAS pathway (1)
- Radiative capture (1)
- Radiative decay (1)
- Rapidity Range (1)
- Rare decays (1)
- Reactions with relativistic radioactive beams (1)
- Registries (1)
- Regulatory networks (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Respiratory infections (1)
- Retinal diseases (1)
- Rhabdomyoma (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SR-BI (1)
- SVR (1)
- Semi-leptonic decays (1)
- Severe malaria (1)
- Single muons (1)
- Single particle decay spectroscopy (1)
- Sociodemographic characteristics (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Sphingolipids (1)
- Sputum smear-negative (1)
- Stentoplasty (1)
- Storage ring (1)
- Subependymal giant cell astrocytoma (1)
- Super-resolution microscopy (1)
- Surgical oncology (1)
- Systematic Uncertainty (1)
- TB-therapy (1)
- TIPS (1)
- TR (1)
- TSC (1)
- Teaching (1)
- Techniques Electromagnetic calorimeters (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- University hospitals (1)
- Universitätskliniken (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- Virtual noncalcium reconstructions (1)
- Weiterbildung (1)
- X-ray computed (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Y states (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- acute myeloid leukemia (1)
- adaptive immunity (1)
- adult and elderly patients (1)
- allogeneic transplantation (1)
- angiography (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- annual bleeding rate (1)
- anterior chamber depth changes (1)
- antigen presentation (1)
- auditory system (1)
- autoimmunity (1)
- biopsy cores (1)
- bone marrow derived mononuclear cells (1)
- cART (1)
- cancer therapy (1)
- cardiac magnetic resonance (1)
- castration resistance (1)
- cataract surgery (1)
- cell-free protein synthesis (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- children (1)
- chronic kidney disease (1)
- clinical stage (1)
- co-infection (1)
- cohlear implant (1)
- cohort study (1)
- collagen degradation marker (1)
- component study (1)
- computer-assisted (1)
- critical size defect (1)
- cryo-EM (1)
- cyanines (1)
- cytarabine dose (1)
- dE/dx (1)
- decision aids (1)
- detector (1)
- dimuon (1)
- dislocation (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e-scooter (1)
- effective lens position (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electric scooter (1)
- electron-positron collision (1)
- embolization (1)
- erectile dysfunction (1)
- experimental results (1)
- exponential model (1)
- external fixation (1)
- fibrosis imaging (1)
- fibrotest (1)
- flow cytometry (1)
- fracture (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- heavy-ion storage rings (1)
- helicity amplitude analysis (1)
- hemodynamic instability (1)
- hemorrhage (1)
- hepatitis C (1)
- high-risk neuroblastoma (1)
- immune reconstitution (1)
- inclusive J/ψ decays (1)
- induced membrane (1)
- interoperability (1)
- intrinsically disordered region (1)
- inverse kinematics (1)
- lactate (1)
- lapatinib (1)
- learning loss (1)
- lung cancer (1)
- mTOR inhibitor (1)
- management (1)
- membrane proteins (1)
- metastasis (1)
- metastatic prostate cancer (1)
- mindfulness (1)
- molecular machines (1)
- molecular tug-of-war (1)
- mortality (1)
- myocardial fibrosis (1)
- neoadjuvant therapy (1)
- neutron-induced reactions (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- nonstructural proteins (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- oxLDL (1)
- p53 pathway (1)
- pIOL (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- peptide editing (1)
- peptide-loading complex (1)
- photoacid (1)
- phylogeny (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- point shear wave elastography (1)
- portal hypertension (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- proteomics (1)
- proton transfer (1)
- pseudoexfoliative syndrome (1)
- psychotherapy process (1)
- quality control (1)
- quark gluon plasma (1)
- randomized controlled trial (RCT) (1)
- registry for primary immunodeficiency (1)
- resectability (1)
- risk group (1)
- scaffold size (1)
- scar (1)
- school closure (1)
- seed and soil (1)
- sequence alignment (1)
- smart home (1)
- smart living (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- spine (1)
- spiro compounds (1)
- stage migration (1)
- structural biology (1)
- structural proteins (1)
- student achievement (1)
- surrogate reactions (1)
- survival (1)
- systematic review (1)
- tapasin (1)
- tetraquark (1)
- therapeutic alliance (1)
- traffic accident (1)
- transient elastography (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- trigger efficiency (1)
- ultrafast spectroscopy (1)
- vertebroplasty (1)
- web of things (1)
- x-ray techniques (1)
- Λ+c baryon (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1303)
- Frankfurt Institute for Advanced Studies (FIAS) (957)
- Informatik (922)
- Medizin (104)
- ELEMENTS (18)
- Geowissenschaften (10)
- Biochemie und Chemie (5)
- Exzellenzcluster Herz-Lungen-System (3)
- Informatik und Mathematik (3)
- Biochemie, Chemie und Pharmazie (2)
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters. We evaluated whether the interplay of both IFNL3 polymorphisms rs12979860 and rs8099917 together with non-genetic clinical factors contributes to the predictive role of these genetic variants.
Methods: The cohort comprised 1,402 patients of European descent with chronic HCV type 1 infection. 1,298 patients received interferon-based antiviral therapy, and 719 (55%) achieved SVR. The IFNL3 polymorphisms were genotyped by polymerase chain reaction and melting curve analysis.
Results: A significant correlation was found between the IFNL3 polymorphisms and biochemical as well as virologic predictors of treatment outcome such as ALT, GGT, cholesterol, and HCV RNA levels. In multivariate regression analysis, IFLN3 SNPs, HCV RNA levels, and the GGT/ALT ratio were independent predictors of SVR. Dependent on the GGT/ALT ratio and on the HCV RNA concentration, significant variations in the likelihood for achieving SVR were observed in both, carriers of the responder as well as non-responder alleles.
Conclusions: Our data support a clear association between IFNL3 genotypes and baseline parameters known to impact interferon responsiveness. Improved treatment outcome prediction was achieved when these predictors were considered in combination with the IFNL3 genotype.
Radiographic and safety details of vertebral body stenting : results from a multicenter chart review
(2013)
Background: Up to one third of BKP treated cases shows no appreciable height restoration due to loss of both restored height and kyphotic realignment after balloon deflation. This shortcoming has called for an improved method that maintains the height and realignment reached by the fully inflated balloon until stabilization of the vertebral body by PMMA-based cementation. Restoration of the physiological vertebral body height for pain relief and for preventing further fractures of adjacent and distant vertebral bodies must be the main aim for such a method. A new vertebral body stenting system (VBS) stabilizes the vertebral body after balloon deflation until cementation. The radiographic and safety results of the first 100 cases where VBS was applied are presented.
Methods: During the planning phase of an ongoing international multicenter RCT, radiographic, procedural and followup details were retrospectively transcribed from charts and xrays for developing and testing the case report forms. Radiographs were centrally assessed at the institution of the first/senior author.
Results: 100 patients (62 with osteoporosis) with a total of 103 fractured vertebral bodies were treated with the VBS system. 49 were females with a mean age of 73.2 years; males were 66.7 years old. The mean preoperative anterior-middle-posterior heights were 20.3-17.6-28.0 mm, respectively. The mean local kyphotic angle was 13.1°. The mean preoperative Beck Index (anterior edge height/posterior edge height) was 0.73, the mean alternative Beck Index (middle height/posterior edge height) was 0.63. The mean postoperative heights were restored to 24.5-24.6-30.4 mm, respectively. The mean local kyphotic angle was reduced to 8.9°. The mean postoperative Beck Index was 0.81, the mean alternative one was 0.82. The overall extrusion rate was 29.1%, the symptomatic one was 1%. In the osteoporosis subgroup there were 23.8% extrusions. Within the three months followup interval there were 9% of adjacent and 4% of remote new fractures, all in the osteoporotic group.
Conclusions: VBS showed its strengths especially in realignment of crush and biconcave fractures. Given that fracture mobility is present, the realignment potential is sound and increases with the severity of preoperative vertebral body deformation.
Background Vasoplegic syndrome is frequently observed during cardiac surgery and resembles a complication of high mortality and morbidity. There is a clinical need for therapy and prevention of vasoplegic syndrome during complex cardiac surgical procedures. Therefore, we investigated different strategies in a porcine model of vasoplegia.
Methods We evaluated new medical therapies and prophylaxis to avoid vasoplegic syndrome in a porcine model. After induction of anesthesia, cardiopulmonary bypass was established through median sternotomy and central cannulation. Prolonged aortic cross-clamping (120 min) simulated a complex surgical procedure. The influence of sevoflurane-guided anesthesia (sevoflurane group) and the administration of glibenclamide (glibenclamide group) were compared to a control group, which received standard anesthesia using propofol. Online hemodynamic assessment was performed using PiCCO® measurements. In addition, blood and tissue samples were taken to evaluate hemodynamic effects and the degree of inflammatory response.
Results Glibenclamide was able to break through early vasoplegic syndrome by raising the blood pressure and systemic vascular resistance as well as less need of norepinephrine doses. Sevoflurane reduced the occurrence of the vasoplegic syndrome in the mean of stable blood pressure and less need of norepinephrine doses.
Conclusion Glibenclamide could serve as a potent drug to reduce effects of vasoplegic syndrome. Sevoflurane anesthesia during cardiopulmonary bypass shows less occurrence of vasoplegic syndrome and therefore could be used to prevent it in high-risk patients.
Clinical Perspective; what is new?
* to our knowledge, this is the first randomized in vivo study evaluating the hemodynamic effects of glibenclamide after the onset of vasoplegic syndrome
* furthermore according to literature research, there is no study showing the effect of sevoflurane-guided anesthesia on the occurrence of a vasoplegic syndrome
Clinical Perspective; clinical implications?
to achieve better outcomes after complex cardiac surgery there is a need for optimized drug therapy and prevention of the vasoplegic syndrome
Purpose: To evaluate intermediate and long-term visual outcomes and safety of a phakic intraocular posterior chamber lens with a central hole (ICL V4c) for myopic eyes.
Methods: Retrospective, consecutive case study of patients that uneventfully received a ICL V4c for myopia correction, with a 5-year postoperative follow-up. Department of Ophthalmology, Goethe University Frankfurt, Germany.
Results: From 241 eyes that underwent ICL implantation, we included 45 eyes with a mean age at surgery of 33 years ± 6 (18–48 years), with a 5 years follow-up. CDVA improved from 0.05logMAR ± 0.15 CDVA preoperatively to − 0.00 ± 0,07 at 5 years and did not change significantly from 3 to 5 years’ time (p = 0.266). The mean spherical equivalent (SE) improved from -10.13D ± 3.39 to − 0.45D ± 0.69. The change in endothelial cell count showed a mean decrease of 1.9% per year throughout the follow-up. Safety and efficacy index were 1.16 and 0.78, respectively. Cataract formation was seen in 2 of 241 eyes (0.8%), but in none of the 45 eyes that finished the 5-year follow-up.
Conclusions: Our data show a good intermediate and long-term stability, efficiency, and safety of ICL V4c phakic lenses in myopic eyes comparable to other known literature.
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Methodology/Principal Findings: Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061–2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D3<20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance: Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable predictor of treatment outcome.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
Background: The sodium-taurocholate cotransporting polypeptide (NTCP) is both a key bile acid (BA) transporter mediating uptake of BA into hepatocytes and an essential receptor for hepatitis B virus (HBV) and hepatitis D virus (HDV). In this study we aimed to characterize to what extent and through what mechanism BA affect HDV cell entry.
Methods: HuH-7 cells stably expressing NTCP (HuH-7/NTCP) and primary human hepatocytes (PHH) were infected with in vitro generated HDV particles. Infectivity in the absence or presence of compounds was assessed using immunofluorescence staining for HDV antigen, standard 50% tissue culture infectious dose (TCID50) assays and quantitative PCR.
Results: Addition of primary conjugated and unconjugated BA resulted in a dose dependent reduction in the number of infected cells while secondary, tertiary and synthetic BA had a lesser effect. This effect was observed both in HuH-7/NTCP and in PHH. Other replication cycle steps such as replication and particle assembly and release were unaffected. Moreover, inhibitory BA competed with a fragment from the large HBV envelope protein for binding to NTCP-expressing cells. Conversely, the sodium/BA-cotransporter function of NTCP seemed not to be required for HDV infection since infection was similar in the presence or absence of a sodium gradient across the plasma membrane. When chenodeoxycolic acid (15 mg per kg body weight) was administered to three chronically HDV infected individuals over a period of up to 16 days there was no change in serum HDV RNA.
Conclusions: Primary BA inhibit NTCP-mediated HDV entry into hepatocytes suggesting that modulation of the BA pool may affect HDV infection of hepatocytes.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.